Brief: Sana Biotechnology Obtains A Non-Exclusive License To CRISPR Cas12b Gene Editing Technology

Sana Biotechnology

19/10/2021 14:34

Oct 19 (Reuters) - Beam Therapeutics Inc  BEAM.O :
    * SANA BIOTECHNOLOGY OBTAINS A NON-EXCLUSIVE LICENSE TO
CRISPR
CAS12B GENE EDITING TECHNOLOGY FROM BEAM THERAPEUTICS TO ENABLE
ENGINEERED CELL PROGRAMS
    * SANA BIOTECHNOLOGY INC - AGREEMENT COMBINES BEAM'S GENE
EDITING
TECHNOLOGY WITH SANA'S EX VIVO PLATFORM
    * SANA BIOTECHNOLOGY INC - UNDER TERMS OF AGREEMENT, SANA
AGREED
TO PAY BEAM AN UPFRONT PAYMENT OF $50 MILLION
    * SANA BIOTECHNOLOGY INC - BEAM IS ALSO ELIGIBLE TO RECEIVE
CERTAIN TARGET OPTION EXERCISE FEES, CERTAIN MILESTONE PAYMENTS

Source text for Eikon:  ID:nGNX33cWKf 
Further company coverage:  BEAM.O 

 ((Reuters.Briefs@thomsonreuters.com;))